Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?

KORKMAZ, Mehmet E.; ATAR, İlyas; AYDINALP, Alp; BOZBAŞ, Hüseyin; EROĞLU, Serpil; Özin, Mehmet Bülent; MUDERRİSOGLU, IBRAHIM HALDUN; YILDIRIR, Aylin; PİRAT, Bahar; Ulus, Taner

Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?

Hüseyin BOZBAŞ, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Aylin YILDIRIR, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Bahar PİRAT, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Serpil EROĞLU, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Mehmet E. KORKMAZ, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

İlyas ATAR, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Taner ULUS, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Alp AYDINALP, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Bülent ÖZİN, (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Haldun MÜDERRİSOĞLU (Başkent Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Anadolu Kardiyoloji Dergisi

0 0

Yıl: 2008 Cilt: 8 Sayı: 2 Sayfa Aralığı: 111 - 115 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?

Öz:

Metabolik sendromu (MS) bulunan hastalar artmış koroner arter hastalığı (KAH) riskine sahiptirler. Yeni tanımlanan koroner risk faktörleri ile MS arasındaki ilişki net olarak bilinmemektedir. Bu çalışmada MS olan ve olmayan hastalarda lipoprotein (a) [Lp(a)], homosistein (Hcy), ürik asid ve C-reaktif protein (CRP) düzeylerinin ölçülmesi amaçlandı. Yöntemler: Kesitsel, kontrollü olarak planlanan çalışmaya hastanemiz kardiyoloji kliniğine ayaktan başvuran 355 hasta (186 MS, 169 kontrol) dahil edildi. MS ATP III kriterlerine göre tanımlandı. Serum Lp(a), Hcy, ürik asid ve CRP düzeyleri ölçülerek gruplar arasında karşılaştırıldı. Bulgular: Gruplar yaş, cinsiyet ve diğer demografik özellikler açısından benzer idi (p >0.05). Bekleneceği üzere hipertansiyon (%85.4 ve %55.6, p<0.001) ve dislipidemi (%78.3 ve %62.6, p<0.05) prevalansı MS olan hastalarda anlamlı şekilde daha fazla idi. Sigara kullanımı (%28.4 ve %24.8, p=0.4) ve ailede KAH öyküsü (%46.1 vs %40.8, p=0.3) ise farklı değildi. Serum Lp(a) düzeyi MS olan hastalarda kontrol grubuna oranla anlamlı şekilde daha yüksek saptandı [29.2 (13.4-45.7) ve 16.2 (9.5-26.2) mg/dL; p<0.0001], ancak Hcy (12.2±4.8 ve 12.3±4.9 µmol/L; p=0.8), ürik asid (5.7±1.6 ve 5.3±1.3 mg/dL; p=0.08) ve CRP [6.0 (3.7-9.3) vs 5.1 (3.2-7.6) mg/L; p=0.07] düzeyleri gruplar arasında benzer bulundu. Sonuç: Bu bulgular MS bulunan hastalarda serum Lp(a) düzeyinin yüksek olabileceğini ve bu hastalarda izlenen erken aterosklerozdan sorumlu olabileceğini düşündürmektedir. Bu konunun daha iyi aydınlatılabilmesi için ileri çalışmalara ihtiyaç vardır.

Anahtar Kelime: Lipoprotein(a) Koroner arter hastalığı Risk faktörleri Homosistein C-reaktif protein Metabolik sendrom X Olgu-kontrol çalışmaları Yaygınlık Ürik asit

Konular: Kalp ve Kalp Damar Sistemi

Metabolik sendromu bulunan hastalarda artmış lipoprotein (a) düzeyi: Erken ateroskleroz gelişimi için bir risk faktörü olabilir mi?

Öz:

It is well known that patients with metabolic syndrome (MS) have a greater risk of developing coronary artery disease (CAD). However, the association of novel coronary risk factors with MS has not been well established. In this study, we sought to investigate the association of lipoprotein (a) [Lp(a)], homocysteine (Hcy), uric acid, and C-reactive protein (CRP) levels with MS. Methods: We enrolled 355 consecutive patients from our outpatient cardiology clinic into this cross-sectional, controlled study-186 with MS and 169 without MS, according to the Adult Treatment Panel III criteria. Serum Hcy, Lp(a), uric acid, and CRP levels were determined and compared between the groups. Results: The groups were homogenous with regard to age, sex, and other demographic variables (all p>0.05). As expected, the prevalence of hypertension (85.4% vs 55.6%, p<0.001) and dyslipidemia (78.3% vs 62.6%, p<0.05) were higher in patients in the MS group. Patients were comparable with respect to smoking (28.4% vs 24.8%, p =0.4) and family history of CAD (46.1% vs 40.8%, p=0.3). Patients with MS had significantly higher Lp(a) levels [29.2 (13.4-45.7) vs 16.2 (9.5-26.2) mg/dL; p<0.0001] compared with controls, whereas Hcy (12.2±4.8 vs 12.3±4.9 µmol/L; P=0.8), uric acid (5.7±1.6 vs 5.3±1.3 mg/dL; p=0.08), and CRP levels [6.0 (3.7-9.3) vs 5.1 (3.2-7.6) mg/L; p=0.07] were similar. Conclusion: Patients with MS seems to have increased serum levels of Lp(a), which might contribute to the premature atherosclerosis observed in these patients. Further research is needed to better clarify this issue.

Anahtar Kelime: C-Reactive Protein Metabolic Syndrome X Case-Control Studies Prevalence Uric Acid Lipoprotein(a) Coronary Artery Disease Risk Factors Homocysteine

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106: 3143-421.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
3. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44: 2301-6.
4. Luc G, Bard JM, Arvelier D, Ferrieres J, Evans A, Amouyel P, et al. PRIME Study Group. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163: 377-84.
5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
6. Yılmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Toruner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258-63.
7. Wassef N, Sidhom G, Zakareya el-K, Mohammed el-K. Lipoprotein(a) in android obesity and NIDDM. Diabetes Care 1997; 20: 1693-6.
8. Akanji AO, al-Shayji IA, Kumar P. Metabolic and antropometric determinants of serum Lp(a) concentrations and Apo(a) polymorphism in a healthy Arab population. Int J Obes Relat Metab Disord 1999; 23: 855-62.
9. Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, et al. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. Am J Epidemiol 1995; 141: 815-21.
10. De Pergola G, Giorgino F, Cospite MR, Giagulli VA, Cignarelli M, Ferri G, et al. Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women. Arterioscler Thromb 1993; 13: 675-9.
11. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994; 90: 1688-95.
12. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
13. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R, et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinol 2004;151:483-9.
14. Meigs JB, Jacques PF, Selhub J, SingerDE, Nathan DM, Rifai N, et al. Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 2001; 24: 1403-10.
15. Rosolova H, Simon J, Mayer O, Racek J, Dierze T, Jacobsen DW. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 2002; 51: 93-8.
16. Abbasi F, Facchini F, Humphreys MH, Reaven GM. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atheroslerosis 1999; 146: 175-8.
17. Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome. J Clin Endocrinol Metab 2001; 86: 719-23.
18. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PWF. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-5.
19. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a population study. Eur J Endocrinol 2003; 149: 601-8.
20. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase phase plasma protein genes. Mol Cell Biol 1992; 12: 1789-97.
21. Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-6.
22. Danesh J, Muir J, Wong YK, Ward M, Galimore JR, Pepys MB. Risk factors for coronary heart disease and acute phase proteins: a population based study. Eur Heart J 1999; 20: 954-9.
23. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
24. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 26: 1546-51.
25. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they they leave us? Am J Med 2005; 118: 816-26.
26. Madsen TE, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Jackson JD, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45-9.
27. Denzer C, Muche R, Mayer H, Heinze E, Debatin KM, Wabitsch M. Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab 2003; 16: 1225-32.
28. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996; 20: 975-80.
29. Cigolini M, Targher G, Tonoli M, Manara F, Muggeo M, De Sandre G. Hyperuricemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord 1995; 19: 92-6.

APA	BOZBAŞ H, YILDIRIR A, PİRAT B, EROĞLU S, KORKMAZ M, ATAR İ, Ulus T, AYDINALP A, Özin M, MUDERRİSOGLU I (2008). Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. , 111 - 115.
Chicago	BOZBAŞ Hüseyin,YILDIRIR Aylin,PİRAT Bahar,EROĞLU Serpil,KORKMAZ Mehmet E.,ATAR İlyas,Ulus Taner,AYDINALP Alp,Özin Mehmet Bülent,MUDERRİSOGLU IBRAHIM HALDUN Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. (2008): 111 - 115.
MLA	BOZBAŞ Hüseyin,YILDIRIR Aylin,PİRAT Bahar,EROĞLU Serpil,KORKMAZ Mehmet E.,ATAR İlyas,Ulus Taner,AYDINALP Alp,Özin Mehmet Bülent,MUDERRİSOGLU IBRAHIM HALDUN Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. , 2008, ss.111 - 115.
AMA	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. . 2008; 111 - 115.
Vancouver	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. . 2008; 111 - 115.
IEEE	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I "Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?." , ss.111 - 115, 2008.
ISNAD	BOZBAŞ, Hüseyin vd. "Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?". (2008), 111-115.

APA	BOZBAŞ H, YILDIRIR A, PİRAT B, EROĞLU S, KORKMAZ M, ATAR İ, Ulus T, AYDINALP A, Özin M, MUDERRİSOGLU I (2008). Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. Anadolu Kardiyoloji Dergisi, 8(2), 111 - 115.
Chicago	BOZBAŞ Hüseyin,YILDIRIR Aylin,PİRAT Bahar,EROĞLU Serpil,KORKMAZ Mehmet E.,ATAR İlyas,Ulus Taner,AYDINALP Alp,Özin Mehmet Bülent,MUDERRİSOGLU IBRAHIM HALDUN Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. Anadolu Kardiyoloji Dergisi 8, no.2 (2008): 111 - 115.
MLA	BOZBAŞ Hüseyin,YILDIRIR Aylin,PİRAT Bahar,EROĞLU Serpil,KORKMAZ Mehmet E.,ATAR İlyas,Ulus Taner,AYDINALP Alp,Özin Mehmet Bülent,MUDERRİSOGLU IBRAHIM HALDUN Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. Anadolu Kardiyoloji Dergisi, vol.8, no.2, 2008, ss.111 - 115.
AMA	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. Anadolu Kardiyoloji Dergisi. 2008; 8(2): 111 - 115.
Vancouver	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?. Anadolu Kardiyoloji Dergisi. 2008; 8(2): 111 - 115.
IEEE	BOZBAŞ H,YILDIRIR A,PİRAT B,EROĞLU S,KORKMAZ M,ATAR İ,Ulus T,AYDINALP A,Özin M,MUDERRİSOGLU I "Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?." Anadolu Kardiyoloji Dergisi, 8, ss.111 - 115, 2008.
ISNAD	BOZBAŞ, Hüseyin vd. "Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?". Anadolu Kardiyoloji Dergisi 8/2 (2008), 111-115.